Johnson & Johnson (JNJ)

122.40
0.33 0.27
NYSE : Health Care
Prev Close 122.73
Open 122.13
Day Low/High 122.10 / 122.88
52 Wk Low/High 105.04 / 126.07
Volume 5.94M
Avg Volume 6.96M
Exchange NYSE
Shares Outstanding 2.72B
Market Cap 331.09B
EPS 6.10
P/E Ratio 20.52
Div & Yield 3.20 (2.60%)

Latest News

Johnson & Johnson Transparency Report Shows 3.5% Increase in Drug Prices

Johnson & Johnson Transparency Report Shows 3.5% Increase in Drug Prices

Johnson & Johnson (JNJ) plans to issue a transparency report annually going forward.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.

Ortho Clinical Diagnostics Awarded Top Honor For Global Excellence In Customer Service

Ortho Clinical Diagnostics Awarded Top Honor For Global Excellence In Customer Service

Ortho Careā„¢ Support Program Recognized As Best-in-Class Service and Support for Hospitals, Hospital Networks, Blood Banks and Labs

Johnson & Johnson Completes Acquisition Of Abbott Medical Optics

Johnson & Johnson Completes Acquisition Of Abbott Medical Optics

Johnson & Johnson Vision will reach more patients globally with expansion into cataract surgery

IBM, Apple, Amazon: Doug Kass' Views

IBM, Apple, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on peak housing, and also discusses Fannie Mae and Freddie Mac's recent kneecapping.

Here's Why Alphabet May Be the Best FANG Stock to Own

Here's Why Alphabet May Be the Best FANG Stock to Own

Google parent Alphabet has the strongest and most diversified long-term growth prospects.

Calling a Market Top; The Price Is Wrong: Jim Cramer's Best Blog

Calling a Market Top; The Price Is Wrong: Jim Cramer's Best Blog

Jim Cramer ponders what motivates someone to call a market top, and talks about how the market could be playing 'The Price Is Wrong.'

Cramer: When Someone Calls a Market Top, What's Their Motivation?

Cramer: When Someone Calls a Market Top, What's Their Motivation?

It's better to be early than wrong. Though being wrong isn't so awful.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Bristol-Myers Buys Back Shares, Shuffles Board

Bristol-Myers Buys Back Shares, Shuffles Board

The drug company will carry out 80% of a $2B repurchase by Feb. 28 after pressure from insurgent Jana Partners. Icahn also reportedly acquired a stake, with focus on M&A.

The Natural Food Craze Is Now Sweeping Into Personal Care Products

The Natural Food Craze Is Now Sweeping Into Personal Care Products

Demand for 'green' consumer products is rising and giants like Procter & Gamble are noticing.

Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More

Hurry Up and Grab Some Johnson & Johnson Before the Stock Bursts Even More

This is what the charts say.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops up JNJ's Codman Neurosurgery for $1.05 Billion

Integra hopes this deal will grow its revenue to $2 billion sooner than expected.

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

Integra Scoops Up JNJ's Codman Neurosurgery for $1.05 Billion

The company hopes the JNJ assets will give revenue growth a boost.

Signs That Upside Is Limited Abound

But is more typical to get a 4% pullback from these sorts of readings than to see the market collapse.

Harley-Davidson: Cramer's Top Takeaways

Harley-Davidson: Cramer's Top Takeaways

Harley needs to keep expanding overseas and taking market share from the competition, says Jim Cramer.

Kratos Defense and Security Solutions: Cramer's Top Takeaways

Kratos Defense and Security Solutions: Cramer's Top Takeaways

Jim Cramer says Kratos is not too big, and not too small, but just the right size to benefit from increased defense spending.

Taser: Cramer's Top Takeaways

Taser: Cramer's Top Takeaways

Taser CEO Rick Smith tells Jim Cramer his company's acquisitions will add AI to its platform to help analyze data for law enforcement.

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

U.S. Steel, Universal Display, Bristol-Myers Squibb: 'Mad Money' Lightning Round

Jim Cramer is bullish on United States Steel and Universal Display, less so with Arconic and Himax Technologies.

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Game Plan for the Week Ahead: Cramer's 'Mad Money' Recap (Friday 2/10/17)

Investors should keep an eye on interest rates and oil, but remember next week is still a week of big earnings reports, says Jim Cramer.

Why Dump Good Stocks?; Gamers, Oil and Industrials Take a Ride: Jim Cramer's Best Blog

Why Dump Good Stocks?; Gamers, Oil and Industrials Take a Ride: Jim Cramer's Best Blog

Jim Cramer ponders what makes people dump good stocks and discusses the ride gamers, oil and industrials took.

Cramer: Why Are People Dumping Such Good Stocks?

Cramer: Why Are People Dumping Such Good Stocks?

Amazon, J&J, IBM and others don't deserve this treatment.

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

Cramer: Like Them or Not (and I Don't), Bonds Set the Tone Today

They have become a referendum on Trump's plans for lower corporate taxes.